Pardes Biosciences (NASDAQ:PRDS) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.50) by 18 percent. This is a 26.79 percent increase over losses of $(0.56) per share from the same period last year.
Oncorus Announces Publication In Nature Communications Highlighting The Development Of Its Intravenously Administered Synthetic vRNA/LNP Platform For The Treatment Of Cancer
ANDOVER, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), a viral immunotherapies company focused on stimulating the immune system to transform outcomes for cancer patients, today announced the
